→
Hologic Inc's revenue growth of only 2.17% year-over-year, combined with an earnings miss in Q1 2026, where actual EPS was $1.042 compared to the estimate of $1.1138, signals underlying weakness. The P/E ratio of 31.20 also suggests the stock may be overvalued, especially against a backdrop of declining EPS growth of -23.76%.
Sell Hologic Inc stock until clearer growth signals emerge.
If Hologic can improve its earnings trajectory, a recovery in EPS could lead to a revaluation of the stock. Additionally, with a current ratio of 4.04, the company has ample liquidity to invest in growth initiatives.
The 20 Hold and 3 Sell ratings in the analyst consensus indicate a lack of confidence in Hologic's growth prospects. Furthermore, the declining EPS growth of -23.76% raises concerns about the sustainability of its profitability.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Helm's AI rates HOLX as Bearish. Sell Hologic Inc stock until clearer growth signals emerge.
The 20 Hold and 3 Sell ratings in the analyst consensus indicate a lack of confidence in Hologic's growth prospects. Furthermore, the declining EPS growth of -23.76% raises concerns about the sustainability of its profitability.
If Hologic can improve its earnings trajectory, a recovery in EPS could lead to a revaluation of the stock. Additionally, with a current ratio of 4.04, the company has ample liquidity to invest in growth initiatives.
Hologic Inc's revenue growth of only 2.17% year-over-year, combined with an earnings miss in Q1 2026, where actual EPS was $1.042 compared to the estimate of $1.1138, signals underlying weakness. The P/E ratio of 31.20 also suggests the stock may be overvalued, especially against a backdrop of declining EPS growth of -23.76%.
Hologic Inc's revenue growth of only 2.17% year-over-year, combined with an earnings miss in Q1 2026, where actual EPS was $1.042 compared to the estimate of $1.1138, signals underlying weakness. The P/E ratio of 31.20 also suggests the stock may be overvalued, especially against a backdrop of declining EPS growth of -23.76%. Our overall verdict is Bearish.
Helm Terminal offers free AI-powered stock analysis for HOLX at helmterminal.dev/analyze/HOLX, updated continuously during US market hours. No signup required.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.